Human Growth Hormone Drugs - Global Strategic Business Report

Description: The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.

Company profiles are primarily based on public domain information including company URLs. The report profiles 28 companies including many key and niche players such as -

- Eli Lilly and Company
- Ferring Holding SA
- Genentech, Inc.
- GeneScience Pharmaceuticals Co., Ltd.
- Merck KgA

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
- Market Outlook
- Evolution of Recombinant Human Growth Hormones (hGH)
- List of Select Approved Prescription Daily-dose hGH Products by Indication
- Patent Expiry Paves Way for the Emergence of Biosimilars; Impact Remains Small
- Strong Innovation Drive Takes Hold of the hGH Industry
- Sizing the Market
- Key Growth Drivers
- High Prevalence of Growth Hormone Deficiency Disorders
- Innovations Hold the Key to Market Growth
- New Indications for hGH Replacement Therapy
- Major Growth Restraining Factors
- Complex Delivery System
- High Cost of hGH Treatment
- Difficulty in Securing Reimbursement
- Biosimilars Threaten Revenue Growth Erosion
- Limited Pharmacological Differences Exist Among Current Agents

2. MARKET TRENDS & ISSUES
- Pediatric GHD Rules, while Adult GHD Remains Underserved
- Table 1: Worldwide Recombinant Human Growth Hormone Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Turner Syndrome & Idiopathic Short Stature; Pediatric GHD; and Others (includes corresponding Graph/Chart)
- Long-Acting hGH Drugs
- a Potential Game Changer
- Select Long-Acting hGH Products in Pipeline by Development Stage
- Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth
- Table 2: Worldwide Biosimilar Demand by Product Category (2013): Percentage Breakdown of Value Sales for Epoetina, Granulocyte Colony-Stimulating Factors (G-CSFs), Interferons, Insulins, Low Molecular Weight
Heparins (LMWH), Recombinant Human Growth Hormones (rhGHs), and Others (includes corresponding Graph/Chart)
Manufacturers Bet on Novel Drug Delivery Technologies
Phase IV Studies Necessitated for First Biosimilars
Needle-less Drug Delivery Systems to Wipe Out of Syringes
Drug Delivery Device Options for Marketed hGH Products
Growing Non-Prescription/Off-Label Usage
A Potential Health Hazard
Oral hGH Secretagogues
An Alternative to Controversial hGH Injections in Professional Sports
Risk of Cancer Necessitates Judicious Use of hGH in Children
Dose Titration
A Key to Achieve Enhanced Tolerability
Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE
hGH
A Highly Consolidated Market
Table 3: Leading Recombinant hGH Products in the Global Market (2015): Annual Sales in US$ Million for Genotropin, Humatrope, Norditropin, Nutropin and Saizen (includes corresponding Graph/Chart)
Overview of Select Leading Marketed hGH Products
Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
the Somatropin Biosimilar
Somatropin Biopartners
Review of Select hGH Products in Pipeline
OPKO's Lagova to be the Earliest of Long-Acting hGHs to Hit the Market
Somavaratana Advances Further in Clinical Trials
Somapacitan Moves Ahead in Development; Nears Commercial Launch
TransCon hGH
the Potential Blockbuster hGH Product in Waiting
HanAll's Vitratropin

4. HUMAN GROWTH HORMONE: AN OVERVIEW
Key Factors Controlling Natural hGH Secretion
Structure of hGH
Functions Performed by hGH in the Human Body
Benefits of Adequate hGH
Effects of Human Growth Hormone Imbalances
Hypopituitarism
Evolution of Growth Hormone Replacement Therapy
Indications for Exogenous hGH Administration
Growth Hormone Deficiency (GHD)
Symptoms of Adult Growth Hormone Deficiency
Idiopathic Short Stature
Noonan Syndrome
Prader-Willi Syndrome
Turner Syndrome
Short Stature Homeobox Gene
Small for Gestational Age
Chronic Renal Insufficiency
Short Bowel Syndrome
Other Medical Conditions
Off-label Applications
Contraindications for Somatropin Therapy
Safety Review of hGH Therapy
Reported Adverse Effects of Inaccurate rhGH Dosages
Risks Involved with Pediatric/Adolescent hGH Replacement Therapy
Risks Involved with Adult hGH Replacement Therapy
5. RECENT INDUSTRY ACTIVITY
NHI Includes JCR Pharmaceuticals's GROWJECT Liquid hGH Formulations in Reimbursement Listing
Ascendis Pharma Commences Phase III Trial on TransCon hGH
Teijin Inks License Deal with Versartis for Somavaran
JCR Pharmaceuticals Obtains Japanese MHLW Approval for Growject® Liquid Formulations
Merck Dissolves Merck Serono and Merck Millipore Brands, Relaunches Merck Brand
EMD Serono and Aeterna Zentaris Finalize Promotional Services Deal for Saizen
Versartis Commences Phase II/III Studies for VRS-317 in Japan
Ferring Pharmaceuticals Obtains FDA Clearance for Name Change of Growth Hormone
Hanmi Introduces Development-Stage Long Acting hGH
Novo Nordisk Obtains FDA Approval for Norditropin® FlexPro® Prefilled Pen
OPKO and Pfizer Ink Agreement for Development of OPKO's Long-acting hGH-CTP
Pfizer Announces Positive Results from Phase 3B Study on Genotropin for SGA in Children

6. FOCUS ON SELECT GLOBAL PLAYERS
Eli Lilly and Company (US)
Ferring Holding SA (Switzerland)
Genentech, Inc. (US)
GeneScience Pharmaceuticals Co., Ltd. (China)
Merck KgaA (Germany)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (US)
Sandoz International GmbH (Germany)

7. GLOBAL MARKET PERSPECTIVE
Table 4: World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 5: World Historic Analysis for Human Growth Hormone Drugs by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 6: World 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region
Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET
1. THE UNITED STATES
A. Market Analysis
Current & Future Analysis
US hGH Market
A Peek into GHD Prevalence and Cost of Treatment
Table 7: US Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
Table 8: US hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Idiopathic Short Stature, Pediatric GHD, Turner Syndrome and Others (includes corresponding Graph/Chart)
FDA Approvals Clear Way for Treating More Children
Major hGH Drugs Available in the US, and FDA Approved Indications
FDA Approval of First Biosimilar
Omnitrope Versus Genotropin
A US Perspective
FDA Issues First Draft of Guidelines for Biosimilar and Interchangeable Biologicals
FDA Regulations Governing hGH Products in the OTC Drugs Market
Alarming Increase in Sales of hGH Drugs for Anti-Ageing Therapy
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 9: The US Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 10: The US Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA
Market Analysis
Table 11: Canadian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: Canadian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN
A. Market Analysis
Current & Future Analysis
Market Overview
Table 13: Japanese Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
Table 14: Japanese hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Pediatric GHD and Others (includes corresponding Graph/Chart)
Competition in the Japanese hGH Market
Table 15: Key Players in the Japanese hGH Market (2012, 2014 & 2016): Percentage Breakdown of Value Sales for Eli Lilly, JCR, Novo Nordisk, Pfizer and Others (includes corresponding Graph/Chart)
Timeline of Major Approvals for JCR Pharmaceutical's hGH Product Growject
Japanese Biosimilar Regulatory Guidelines
Sandoz' Omnitrope
the First Biosimilar hGH Launched in Japan
Strategic Corporate Developments
B. Market Analytics
Table 16: Japanese Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: Japanese Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE
A. Market Analysis
Current & Future Analysis
Pediatric GHD
Leading Target Indication for hGH Products
Table 18: European Patient Volumes Receiving Growth Hormone Therapy by Indication (2016E): Breakdown of Number of Patients in Thousands for Adult GHD, Pediatric GHD and Other Indications (includes corresponding Graph/Chart)
Table 19: European hGH Market by Indication (2016E): Percentage Breakdown of Value Sales for Adult GHD, Pediatric GHD and Others (includes corresponding Graph/Chart)
European hGH Market Focuses on Product Differentiation to Revitalize Sales
Regulations Pertaining to Biosimilars in the EU
Table 20: Adoption Rates for hGH Biosimilar in Major Western Europe Markets: 2016 (includes corresponding Graph/Chart)
New Indications Could Drive Growth
B. Market Analytics
Table 21: European Recent Past, Current and Future Analysis for Human Growth Hormone Drugs by Geographic Region
France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 22: European Historic Analysis for Human Growth Hormone Drugs by Geographic Region
France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 23: European 14-Year Perspective for Human Growth Hormone Drugs by Geographic Region
Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE
Market Analysis
Table 24: French Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 25: French Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4b. GERMANY
A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
Key Players
B. Market Analytics
Table 26: German Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 27: German Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4c. ITALY
Market Analysis
Table 28: Italian Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 29: Italian Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
Market Analysis
Table 30: The UK Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 31: The UK Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4e. SPAIN
Market Analysis
Table 32: Spanish Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33: Spanish Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4f. REST OF EUROPE
A. Market Analysis
Current & Future Analysis
Strategic Corporate Development
Select Key Players
B. Market Analytics
Table 34: Rest of Europe Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 35: Rest of Europe Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A. Market Analysis
Current & Future Analysis
Biosimilar Regulations In Asian Countries
South Korea
China
India
Genescience Pharmaceuticals Co., Ltd.
A Leading Chinese Player
B. Market Analytics
Table 36: Asia-Pacific Recent Past, Current and Future Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 37: Asia-Pacific Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD
Market Analysis

Table 38: Rest of World Recent Past, Current and Future Analysis for Human Growth Hormone Drugs
Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding
Graph/Chart)
Table 39: Rest of World Historic Analysis for Human Growth Hormone Drugs Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 28 (including Divisions/Subsidiaries 33)

- The United States (10)
- Canada (1)
- Japan (2)
- Europe (10)
  - Germany (4)
  - The United Kingdom (2)
  - Rest of Europe (4)
- Asia-Pacific (Excluding Japan) (9)
- Middle East (1)

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Human Growth Hormone Drugs - Global Strategic Business Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2255354/">http://www.researchandmarkets.com/reports/2255354/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC2GBGPG</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

| Electronic (PDF) - Single User: |
|---------------------------------|---|
|ISKFRCCJULR | USD 4950 |

| Electronic (PDF) - 1 - 5 Users: |
|---------------------------------|---|
|ISKFRCCJULR | USD 6930 |

| Electronic (PDF) - 1 - 10 Users: |
|---------------------------------|---|
|ISKFRCCJULR | USD 9405 |

| Electronic (PDF) - 1 - 15 Users: |
|---------------------------------|---|
|ISKFRCCJULR | USD 11880 |

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World